Summary Cervical intraepithelial neoplasia (CIN) grades I to III lesions (n = 94) and squamous cell carcinomas of the uterine cervix (n = 27) were analysed for MHC class I and II expression and presence of HPV genotypes.
A central role in the antigen-specific immune response is played by the major histocompatibility complex (MHC), which are cell surface proteins that act as restricting elements in the recognition of antigen by T-cells. MHC class I (MHC-I) present endogenous antigen to cytotoxic T-lymphocytes (CTLs). Low levels or lack of MHC-I surface expression can consequently render aberrant cells non-immunogenic to CTLs, and may provide a way for cells to escape immune surveillance. MHC-1 alterations have been described in human cancer of different sites of the body (see review RuizCabello et al., 1991) .
Generally, MHC class II (MHC-II) surface expression is restricted to specialised antigen presenting cells (APCs) , that present mainly opsonised exogenous antigen to T-helper cells. Recognition leads to activated T-cells, which can stimulate B-cell, CTL proliferation and MHC non-restricted killing by natural killer (NK) cells or activated macrophages. Occasionally, other cells like neoplastic epithelial cells have been described to express MHC-II, which could assist in the onset of the cellular immune response (Ostrand-Rosenberg et al., 1991) .
Infections with specific human papillomavirus (HPV) types are strongly associated with the development of cervical cancer, with HPV types 16 and 18 as the most predominant types (Zur Hausen, 1989) . This is supported by the increasing prevalence of HPV 16/18 with increasing severity of dysplasia to cervical carcinoma (van den Brule et al., 1991; Lungu et al., 1992) and the capacity of these viruses to transform in vitro their natural host cells, the keratinocytes. These cells are immortalised (Durst et al., 1987; Pirisi et al., 1987) and show abnormal differentiation (McCance et al., 1988; Woodworth et al., 1990) , but are initially non-tumorigenic in animals.
This indicates that additional events besides infections with high risk HPVs are involved in the pathogenesis of cervical cancer. These events may include activation of cellular protooncogenes, genetic inactivation of tumour suppressor genes, HPV integration into the cellular genome and failure of immune surveillance (Zur Hausen, 1989a expression of MHC-I and -II is present in a substantial number of HPV 16/18 DNA containing cervical carcinomas (Connor & Stern, 1990 ; Glew et al., 1992) , suggesting that changes in the presentation of viral tumour antigens to the cellular immune system can occur. However, to get insight whether altered MHC-I and -II expression is related to the development of cervical cancer from its premalignant lesions, it is necessary to study dysplastic cervical lesions (CIN) for the MHC-I and -II status.
Tumour virus based mechanisms have been described that specifically influence MHC-I cell surface expression (Signas et al., 1982; Schrier et al., 1983) . Similar mechanisms could exist for HPV affecting antigen presentation of the infected cells. However, little is known about MHC alterations in CIN lesions in relation to the presence of different HPV genotypes.
Therefore in this study expression of MHC-I and -II was investigated in CIN lesions of different grades and cervical carcinomas. HPV typing was carried out by a combined general primer-mediated (GP-) and type-specific (TS-) polymerase chain reaction (PCR) strategy (van den Brule et al., 1991; Walboomers et al., 1992) . In addition, HPV RNA in situ hybridisation (RISH) was applied to some HPV 16 PCR positive lesions, in order to localise cells containing transcriptionally active HPV 16 in relation to altered MHC expression. The results indicate that MHC-I and -II alterations are also present in CIN lesions, independent from the presence of HPV DNA.
Materials and methods

Tissues
Tissues were obtained from patients attending the oncological gynaecological outpatient department from the Free University Hospital, Amsterdam, for routine diagnostic and therapeutic procedures. Clinical material ranged from colposcopically directed punch biopsies to resection specimens. Formalin fixed, paraffin embedded tissues were cut to 4 ym thick consecutive sections for MHC expression analysis by immunohistochemistry and for PCR analysis, sandwiched by two sections for haematoxylin-eosin (HE) staining. CIN lesions were histologically reviewed by two pathologists on both HE stained sections. In case of disagreement a consensus diagnosis was reached. CIN lesions were classified as grade I, II or III, depending on the thickness of the epithelium involved by dysplastic cells. Thus grade 1 CIN represents less than one third involvement of the thickness of the epithelium, grade II one third to two third, and grade III two third to full thickness (Richart, 1987) .
Immunohistochemistry
Paraffin embedded sections on coated slides (0.1% Poly-Llysine) were deparaffinised with xylene, rehydrated and endogenous peroxidase was blocked by incubating 30min with methanol, containing 0.3% H202. After rinsing in PBS, sections were treated as follows for the different primary antibodies: for Pan keratin sections were incubated with trypsin (0.5% w/v) in 0.5% CaC12 (pH 7.8) for 30 min at 370; for RaHC sections were treated with 0.2 M NaAc (pH 4.8) for 15 min at RT; for LN3 sections were treated with a saturated solution of lead thiocyanate for 2 x 5 min at 100GC. After washing repeatedly in PBS, sections were preincubated with normal goat (1:20) or horse (1:50) serum, depending on the secondary antibodies used, for 20 min and incubated with specific antibodies. The following primary antibodies were incubated at RT for 30 min: polyclonal RaHC, 1:500, specific for HLA-A, -B and -C heavy chains (Stam et al., 1986) ; monoclonal antibody (MoAb) HC10, 1:800, preferentially recognising HLA-B and -C locus products (Stam et al., 1986) ; Polyclonal Pan Keratin, 1:400, recognising a broad spectrum of cytokeratins (Dako Patts, Glostrup, Denmark). MoAb LN3, 1:25, recognising HLA-DR antigens (Biotech, Breieich, FRG) was incubated overnight at 4°C.
Monoclonal antibodies (LN3, HC1O) were detected by a biotinylated horse-anti mouse Ab 1:500 (Vector Lab, Burlingame, USA), polyclonals (RaHC, Polyclonal Keratin) with biotinylated goat anti-rabbit 1:500 (Vector Lab). All secondary antibodies were diluted in PBS, containing 2% (v/v) human serum and 1% (w/v) bovine serum albumin (Sigma, Deisenhofen, FRG). Detection was performed using horse radish peroxidase coupled to avidin-biotin complex (Vector Elite, Vector Lab), after which the complex was visualised using diaminobenzidine and H202. Slides were counterstained with haematoxylin, dehydrated and mounted in Depex.
Immunohistochemical staining was analysed independently by two observers. In case of disagreement staining results were re-analysed by the observers together. (Boehringer Mannheim, Mannheim, FRG) was added and the mixture was incubated at 55°C for several hours. Samples were then treated at 100G for 10 min and centrifuged. Twenty ll of the supernatant was used in the PCR reaction. The PCR was performed with general primers (GP 5/6), recognising both sequenced and unsequenced HPV genotypes (Snijders et al., 1990) . HPV DNA positive samples were then subjected to type-specific PCR, performed with primers specific for HPV 6, 11, 16, 18, 31 and 33 (van den Brule et al., 1990) . Samples positive in the general primer mediated PCR which were negative by typespecific PCR were classified as unsequenced or unidentified HPV genotypes (named HPV X). Cells from SiHa and Hela cell lines, which contain HPV 16 and 18 DNA respectively, served as positive controls for the HPV PCR. Amplification products were analysed by 1.5% agarose gel electrophoresis and Southern blot analysis using HPV-specific probes. Nucleotide sequences of primers and probes used in the PCR, as well as the conditions were published elsewhere Walboomers et al., 1992) . As a negative control liver sections were cut in between the different specimens and also subjected to PCR analysis. To analyse the quality of target DNA for PCR purposes samples were analysed by PCR using human ,B-globin gene specific primers. Only P-globin PCR positive samples were included in the study.
RNA in situ hybridisation RNA in situ hybridisation was performed non-radioactively on 4 tm thick tissue sections as previously described by Oudejans et al. (1989) . Briefly, tissue sections on coated (0.1% poly-L-lysine) slides were air dried overnight at 37°C and deparaffinised by overnight incubation in xylol at 50GC. After progressive rehydration, sections were treated with Lugol's iodine and sodium thiosulphate, washed in phosphate-buffered saline, pH 7.4 (PBS), and treated subsequently with proteinase K (0.1-1 g ml-' in 50 mM Tris HCG, pH 7.6, 5 mM EDTA) for 15 min at 37GC. After washing in PBS, sections were postfixed in 4% (w/v) phosphate buffered paraformaldehyde, pH 7.4, for 10 min at room temperature, and washed for 5 min in PBS. Hybridisation mixture, containing 50% (v/v) deionised formamide, 2 x SSC (1 x SSC = 0.15 M NaCl, 0.015 M Na-citrate), 10% (w/v) dextran sulphate, yeast tRNA (50 ytg ml-') (Boehringer Mannheim) and saturation levels of biotinylated probe, were applied to the sections followed by heating to 65°-70°C for 7 min. Hybridisation was allowed to occur for 2 h at 50°C. After hybridisation, sections were washed in 0.1 x SSC at 68°C for 60 min, and non-specifically bound RNA-probe was removed using 0.5-1 mgml-' RNAse A (Boehringer Mannheim) in 10mM Tris HCI, pH 8.2, 1 mM EDTA and 0.5 M NaCl for 15 min at 37°C. Sections were washed once again in 0.1 x SSC for 30min at 68°C.
The HPV-16 E7-specific probe (clone 72 kindly provided by Dr H. Smits, Department of Virology, University of Amsterdam) is directed against nt 622-879. An actin probe was used as positive control probe, derived from a human P-actin cDNA (Clontech Lab., Palo Alto, USA) and is specific for the 5' part of the mRNA. Construction of both probes has been described elsewhere (van den Brule et al., 1991a) . Biotinylated RNA transcripts, both sense and antisense orientations, were generated using biotin-11 UTP (Sigma) and SP6 or T7 RNA polymerase, following manufacturer's instructions (Promega, Madison, USA). RNA-probes were precipitated with ethanol, pellets were dissolved in distilled water containing 400 units ml-' RNaseIn (Promega), diluted in 500 yl deionised formamide containing 50 fg ml' yeast tRNA (Boehringer Mannheim) and stored at -80G.
Integrity and concentration of probes were determined by Northern blot analysis of serial dilutions of both sense and antisense probes. RNAs were visualised using horse radish peroxidase coupled to avidin-biotin complex (Vector Lab) and diaminobenzidine.
RNA-RNA hybrids were detected immunohistochemically by successive incubations with 1:500 dilution of rabbit antibiotin immunoglobulin (Enzo Biochemicals, Farmingdale, USA), 1:250 dilution of biotin-labelled goat anti-rabbit antibody (Vector Lab), both 30 min at room temperature and I:100 dilution of colloidal gold labelled streptavidin (5 nm (Cork, Ireland) .
Results
MHC class I and II expression
General antigen conservation in the sections was ascertained with a polyclonal keratin antibody, recognizing a broad spectrum of cytokeratins. All specimens used in this study showed positive staining with the pan keratin antibody. MHC-I heavy chain expression was analysed using two antibodies, polyclonal RaHC and monoclonal HC10. In general, staining with HCG0 showed more clearly cell surface localisation of the MHC-I complex on keratinocytes. However, no cases were found that showed different results in MHC-I expression with RaHC and HC1O.
Normal epithelium, where present in the section, showed staining for MHC-I on cells at the basal side of the epithelial layer, as well as stromal and immunocompetent cells ( Figure  la The number of lesions, scored as disturbed for MHC-I expression, i.e. 75% or more of the dysplastic cells show strongly reduced to negative staining, was 11 out of 34 CIN I, 10 out of 32 CIN II and 12 out of 28 CIN III lesions. In carcinomas 13 out of 27 cases were scored as disturbed. Heterogeneity of MHC-I expression, i.e. 25 to 75% of the dysplastic cells show strongly reduced to negative staining, was scored in 12 out of 34 CIN I, 15 out of 32 CIN II and 12 out of 28 CIN III lesions. In carcinomas 9 out of 27 cases were scored as heterogenous.
MHC-II expression was determined using LN3, staining HLA-DR locus products. In normal epithelium only a few immunocompetent cells are stained (Figure 2a Figure 3 . An increase of HPV prevalence was associated with an increase of the severity of the lesion. In CIN I, CIN II and CIN III/cervical carcinomas an HPV prevalence of 68%, 91% and 100% was found, respectively. Also the contribution of the HPV types associated with cervical carcinoma (type 16, 18 and 31) increased from 53% in CIN I, 75% in CIN II to 96% in CIN III and 100% in cervical carcinomas. Other HPV types, i.e. HPV 6 and HPV X, were found only in CIN I and II (n = 11), whereas in none of the samples HPV 11 or 33 could be detected.
Association between presence of HP V genotype and MHC alterations All three MHC-I expression patterns (i.e. normal, heterogenous and altered) were observed in lesions, positive for 'high-risk' HPV types 16, 18 or 31. Also in lesions, positive for HPV 6, X or negative for any HPV genotype, all three MHC patterns could be found. Using statistical analysis no significant differences in MHC-I expression patterns could be established between the different HPV containing and the HPV negative lesions (P-value>0.01).
Both normal and upregulated MHC-II expression was observed on dysplastic cells of lesions, positive for 'high-risk' HPV types, as well as in lesions, positive for HPV 6, X or negative for any HPV genotype. No significant differences in MHC-II expression could be established by statistical analysis between the different HPV containing and HPV negative lesions (P-value>0.01). The results are summarised in Table   II. To find out whether HPV, if present, is localised in the same dysplastic cells from which MHC status was determined, additional RNA in situ hybridisation (RISH) was performed on consecutive sections, using an E7-specific RNA probe. Several PCR HPV 16 DNA positive CIN lesions and cervical carcinomas were analysed with RISH, and two typical examples of CIN lesions are shown in Figure 4 . An MHC-I positive CIN II lesion is shown with membranous staining of dysplastic cells at the basal side of the epithelial layer (Figure 4a ). RISH reveals presence of HPV 16-E7 transcripts in the same area, with signals restricted to the dysplastic cells (Figure 4b ). In Figure 4c and d a detail of a CIN I lesion is shown with heterogenous staining for MHC-I heavy chains in the dysplastic cells. Also in this dysplastic area HPV 16-E7 mRNAs can be detected (Figure 4d ). The E7 sense RNA-probe was used as a negative control and gave no signal (not shown). Also in nine carcinomas, described earlier (van de Brule et al., 1991a) , HPV 16 E7 transcripts were found in all carcinoma cells. In these samples both normal and altered MHC-I and -II expression could be detected. (Andersson et al., 1991) , small cell lung cancer (Doyle et' al., 1985) , breast cancer (Fleming et al., 1981) and melanomas (Brocker et al., 1985) . Also in cervical carcinomas this phenomenon has been observed in a substantial number of the carcinomas examined (Connor & Stern, 1990) . However, the role of this phenomenon in the development of these malignancies is as yet unclear.
In this study formalin fixed, paraffin embedded material of reduced or alternatively large modifications have taken place affecting the recognition by both antibodies.
The percentage of MHC-I downregulation (heterogenous and disturbed patterns) in carcinomas in our study (77%) is comparable with the percentage of complete and allelespecific down-regulation taken together in the carcinoma group studied by Connor & Stern (1990) . However, when only analysing complete loss of MHC-I expression the percentage of carcinomas showing MHC-I alterations observed using HCIO and RaHC (48%) was considerably higher than obtained with W6/32 (9%) by Connor & Stern (1990) . The monoclonal antibody W6/32 recognises MHC-I heavy chains, complexed with P2-microglobulin, and is reactive only on frozen tissue, whereas HCIO and RaHC used in our study recognise MHC-I heavy chain antigens both in frozen and paraffin embedded tissue (Stam et al., 1990 Changes in MHC-II expression were detected as well in a substantial number of CIN lesions and cervical carcinomas. MHC-II upregulation on epithelial cells could enhance tumor-specific immunity by bypassing the classical antigen presenting cell (APC) mediated route and directly presenting antigen in the context of MHC-II to T-helper cells (OstrandRosenberg et al., 1991) . This would result in a shorter and faster pathway of local lymphokine production, giving help to CTL-mediated killing and possibly also to other cells like natural killer cells. This could explain the favourable prognosis of tumours expressing MHC-II antigens (Esteban et al., 1990; Gutierrez et al., 1987) . However, upregulation of MHC-II expression in melanoma is reported to be associated with a shorter disease-free survival (Ruiter et al., 1986) (Ferguson et al., 1985; Glew et al., 1992) and in CIN lesions (Warhol et al., 1989 Aberrant MHC-I expression could be observed in HPV negative lesions, as well as lesions containing high-risk HPVs (i.e. HPV 16, 18 and 31) and HPV types 6 or X, as determined by PCR. Normal MHC-I expression patterns were also found in all these groups. This indicates that variations of MHC-I expression are not directly correlated with the presence of specific HPV genotypes. Also no correlation could be found between MHC-II expression and presence of any of the HPV types either, which suggests that the process of upregulation of MHC-II is not related to the presence of HPV DNA. This is in agreement with the observation on cervical carcinomas by Connor & Stern (1990) and Glew et al. (1992) , using Southern blot analysis for HPV typing. Since the PCR, performed on cell extracts, cannot supply morphological information on HPV distribution additional in situ hybridisation was carried out to establish that changes in MHC expression and HPV presence were localised in the same dysplastic/neoplastic cells. For optimal sensitivity of HPV detection RNA instead of DNA in situ hybridisation was performed, because with the latter method low copy numbers of HPV genotypes might not be detected (Walboomers et al., 1988) . The HPV 16-E7 RNA probe was used for this purpose since this gene is highly expressed in HPV transformed cells and E7 transcripts can be detected in all neoplastic cells of HPV 16 containing cervical carcinomas (van den Brule et al., 1991a) . Results showed that E7 transcripts were found in cells with normal as well as in cells with changes in MHC expression in CIN lesions and carcinomas. This indicates that presence of E7 transcripts alone does not result in altered MHC expression. Further transcriptional analysis is necessary to reveal whether other HPV encoded proteins play a role in aberrant expression of MHC-I or -II.
Since the expression of several early and all late HPV genes can be influenced by HPV DNA integration, also the HPV physical state could be an important factor and needs to be further analysed.
Recently we have investigated HPV 16 E7 transcriptionally active cervical carcinomas (van den Brule et al., 1991a), which show a disturbed MHC-I expression using RISH with heavy chain locus-specific antisense RNA probes. All carcinomas, that show MHC-I downregulation as detected with HC10, showed abundant MHC-I heavy chain transcripts in carcinoma cells. This indicates that down-regulation occurs at the post-transcriptional level (Walboomers et al., abstract PV workshop Seattle 1991, manuscript in preparation) . Similar studies have to be performed for MHC-II expression using RISH, to establish if upregulated MHC-II expression occurs at the transcriptional or post-transcriptional level.
Finally, it has also to be taken into consideration that the biological behaviour of CIN lesions is very heterogenous and cannot be predicted by a single histological observation. In general it is assumed that only a minority of CIN lesions show progression to invasive cancer (Richart, 1987) . This means that from randomly taken CIN lesions only a small percentage (approximately 10%) represent progressive CIN. Therefore it seems important to define the clinical parameters of the study groups when MHC expression levels in CIN lesions are compared with results obtained by others. CIN lesions analysed in this study originated from a selected group of women attending the oncological gynaecological clinic, having a high recurrency rate of CIN and are more prone to develop cervical cancer. Currently, this study is extended with CIN lesions of patients that could be retrospectively (Gaarenstroom et al., submitted) and prospectively defined on clinical behaviour. Patients, exhibiting regressive, progressive or persistent CIN disease will be analysed for MHC expression and presence of HPV genotypes. These data will give information about the biological significance of disturbed MHC-I expression, as detected by HCGO and RaHC, as well as W6/32.
